Get the Stockscreener App
4.42
4.25%
0.18
After Hours:
4.45
0.03
+0.68%
Atea Pharmaceuticals Inc stock is traded at $4.42, with a volume of 356.22K.
It is up +4.25% in the last 24 hours and down -21.21% over the past month.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.
See More
Previous Close:
$4.24
Open:
$4.28
24h Volume:
356.22K
Relative Volume:
0.80
Market Cap:
$353.72M
Revenue:
$351.37M
Net Income/Loss:
$-158.35M
P/E Ratio:
-2.264
EPS:
-1.9523
Net Cash Flow:
$-132.03M
1W Performance:
+7.80%
1M Performance:
-21.21%
6M Performance:
+48.82%
1Y Performance:
+55.09%
1-Day Range:
$4.26
$4.44
1-Week Range:
$4.04
$4.44
52-Week Range:
$2.78
$6.45
Atea Pharmaceuticals Inc Stock (AVIR) Company Profile
Name
Atea Pharmaceuticals Inc
Sector
Industry
Phone
(857) 284-8891
Address
225 FRANKLIN STREET, BOSTON
Compare AVIR vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVIR
Atea Pharmaceuticals Inc
|
4.42 | 339.31M | 351.37M | -158.35M | -132.03M | -1.9523 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Atea Pharmaceuticals Inc Stock (AVIR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-24 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Aug-10-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-06-22 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-18-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-20-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-05-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-25-20 | Initiated | Evercore ISI | Outperform |
| Nov-24-20 | Initiated | JP Morgan | Overweight |
| Nov-24-20 | Initiated | Morgan Stanley | Overweight |
| Nov-24-20 | Initiated | William Blair | Outperform |
View All
Atea Pharmaceuticals Inc Stock (AVIR) Latest News
Atea Pharmaceuticals (AVIR) Shows Modest Uptick, Holding Above Key SupportCommunity Pattern Alerts - Newser
AVIR SEC FilingsAtea Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Atea Pharmaceuticals director Polly Murphy buys $25,446 in stock - Investing.com
Atea Pharmaceuticals (AVIR) director buys 6,100 shares of stock - Stock Titan
Atea Pharmaceuticals Q1 earnings call highlights - MSN
Atea (AVIR) director adds 6,100 shares in open-market purchase - Stock Titan
Atea Pharma (AVIR) Stock: Up +1.69%, Key Resistance at $4.42 2026-05-19Community Exit Signals - Newser
Here's Why We're Watching Atea Pharmaceuticals' (NASDAQ:AVIR) Cash Burn Situation - Yahoo Finance
Down 25% in 4 weeks, here's why Atea Pharmaceuticals (AVIR) looks ripe for a turnaround - MSN
Earnings call transcript: Atea Pharmaceuticals Q1 2026 reveals stock plunge after EPS miss By Investing.com - Investing.com South Africa
Earnings call transcript: Atea Pharmaceuticals Q1 2026 reveals stock plunge after EPS miss - Investing.com Nigeria
Down 25% in 4 Weeks, Here's Why Atea Pharmaceuticals (AVIR) Looks Ripe for a Turnaround - Yahoo Finance
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Ibio (IBIO), MaxCyte (MXCT) and Atea Pharmaceuticals (AVIR) - The Globe and Mail
Atea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipeline - Sahm
We Think Atea Pharmaceuticals (NASDAQ:AVIR) Needs To Drive Business Growth Carefully - Sahm
Atea Pharmaceuticals Sets Up Catalyst-Rich 2026 Earnings Call - TipRanks
Atea Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q1 2026 Earnings Call Transcript - Insider Monkey
Atea Pharmaceuticals Announces Three Accepted Abstracts for Presentation at EASL Congress 2026 - Quiver Quantitative
Atea Pharmaceuticals to Present Three Abstracts at EASL - GlobeNewswire
Atea anticipates Phase III C-BEYOND midyear and C-FORWARD year-end readouts while projecting cash runway through 2027 - MSN
Atea Pharmaceuticals, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:AVIR) 2026-05-12 - Seeking Alpha
Earnings call transcript: Atea Pharmaceuticals Q1 2026 reports slight EPS miss, stock dips - Investing.com Nigeria
Atea Pharmaceuticals Q1 Earnings Call Highlights - Yahoo Finance
Atea Pharmaceuticals Q1 2026 Earnings Call: Complete Transcript - Benzinga
[10-Q] Atea Pharmaceuticals, Inc. Quarterly Earnings Report - Stock Titan
Atea Pharmaceuticals Reports First Quarter 2026 Financial Results - TradingView
Atea Pharmaceuticals reports Q1 2026 net loss $45.4M, cash & marketable securities $256.0M - TradingView
Atea Pharmaceuticals (NASDAQ:AVIR) Q1 Loss Narrows as HCV and HEV Pipeline Catalysts Loom - ChartMill
Atea Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
AVIR: HCV and HEV programs advance toward key milestones as R&D spending drives higher net loss - TradingView
Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Atea (NASDAQ: AVIR) advances HCV, HEV pipeline as Q1 loss widens - Stock Titan
Atea Pharmaceuticals : Q1 26 IR Slide Deck 5 12 26 FINAL - marketscreener.com
Atea Pharmaceuticals Inc (AVIR) Q1 2026 Earnings Call Highlights: Strategic Advancements and ... By GuruFocus - Investing.com Canada
TradingKey - TradingKey
Atea Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Corcoran Andrea - Moomoo
[SCHEDULE 13G/A] Atea Pharmaceuticals, Inc. Amended Passive Investment Disclosure - Stock Titan
Atea sets May 12 webcast for quarterly results and business update - Stock Titan
Atea Pharmaceuticals to Host First Quarter 2026 Financial Results and Business Update Conference Call on May 12, 2026 - The Manila Times
Atea Pharmaceuticals to Host First Quarter 2026 Financial Results and Business Update ... - Caledonian Record
Atea Pharmaceuticals (AVIR) price target increased by 25.00% to 10.20 - MSN
AVIR | Atea Pharmaceuticals, Inc. Common Insider Trading - Quiver Quantitative
William Blair Maintains Atea Pharmaceuticals(AVIR.US) With Buy Rating - Moomoo
Atea Pharmaceuticals (NASDAQ: AVIR) sets 2026 proxy votes and outlines late-stage HCV strategy - Stock Titan
AVIR Stock Chart | ATEA PHARMACEUTICALS INC (NASDAQ:AVIR) - ChartMill
Atea Pharmaceuticals (NASDAQ:AVIR) Stock Price Up 1.6%Still a Buy? - MarketBeat
AVIR (Atea Pharmaceuticals Inc.) falls 3% after reporting a wider-than-expected Q4 2025 loss per share.Community Driven Stock Picks - Cổng thông tin điện tử tỉnh Lào Cai
Atea Pharma (AVIR) Stock: Investment Risks (Buying Pressure) 2026-04-20Expert Insights - Cổng thông tin điện tử tỉnh Tây Ninh
Atea Pharma (AVIR) Stock: Worthwhile Investment? (+0.70%) 2026-04-18Breakout Signals - Xã Châu Thành
AVIR Forecast, Price Target & Analyst Ratings | ATEA PHARMACEUTICALS INC (NASDAQ:AVIR) - ChartMill
Atea Pharmaceuticals Inc Stock (AVIR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Atea Pharmaceuticals Inc Stock (AVIR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sommadossi Jean-Pierre | President, CEO, and Chairman |
Feb 03 '26 |
Option Exercise |
1.24 |
300,000 |
372,000 |
767,830 |
| Murphy Polly A. | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
86,045 |
| BERGER FRANKLIN M | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
506,497 |
| Duncan Barbara Gayle | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
62,750 |
| Polsky Bruce | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
95,206 |
| Adams Jerome M. | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
62,750 |
| Lucidi Bruno | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
112,750 |
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):